Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexa B Kimball

Showing results (141-150 of 230) with videos related to

Pageof 23
Sort By:
The Journal of Investigative Dermatology|January 17, 2017
Prevalence and Risk of Inflammatory Bowel Disease in Patients with Hidradenitis SuppurativaAlexander Egeberg, Gregor B E Jemec, Alexa B Kimball, et al.
Journal of the American Academy of Dermatology|March 28, 2019
Reply to: "Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment"Kevin T Savage, Kelsey S Flood, Sabrina Popatia, et al.
Plastic and Reconstructive Surgery|October 26, 2022
Surgical Management of Hidradenitis Suppurativa: A Two-Center Retrospective StudyRyoko Hamaguchi, Taylor L Wearda, Angela S Volk, et al.
Journal of the American Academy of Dermatology|May 20, 2019
Examining the prior authorization process, patient outcomes, and the impact of a pharmacy intervention: A single-center reviewSabrina Popatia, Kelsey S Flood, Nicole M Golbari, et al.
JAMA Dermatology|December 15, 2021
Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis: 1-Year Results From the RELIEVE-AD StudyBruce Strober, Usha G Mallya, Min Yang, et al.
Journal of the American Academy of Dermatology|January 17, 2012
Risks of developing psychiatric disorders in pediatric patients with psoriasisAlexa B Kimball, Eric Q Wu, Annie Guérin, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|January 26, 2017
The Impact of Administrative Burden on Academic Physicians: Results of a Hospital-Wide Physician SurveySandhya K Rao, Alexa B Kimball, Sara R Lehrhoff, et al.
International Journal of Women'S Dermatology|May 27, 2022
Treatment of hidradenitis suppurativa resolves associated hematologic abnormalitiesPeyton C Morss-Walton, Charlotte Greif, Zachary E Holcomb, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trialAndrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Journal of Drugs in Dermatology : JDD|August 21, 2018
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two YearsChristopher E M Griffiths, Kim A Papp, Alexa B Kimball, et al.
Pageof 23

Showing results (141-150 of 230) with videos related to

Sort By:
Pageof 23
The Journal of Investigative Dermatology|January 17, 2017
Prevalence and Risk of Inflammatory Bowel Disease in Patients with Hidradenitis SuppurativaAlexander Egeberg, Gregor B E Jemec, Alexa B Kimball, et al.
Journal of the American Academy of Dermatology|March 28, 2019
Reply to: "Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment"Kevin T Savage, Kelsey S Flood, Sabrina Popatia, et al.
Plastic and Reconstructive Surgery|October 26, 2022
Surgical Management of Hidradenitis Suppurativa: A Two-Center Retrospective StudyRyoko Hamaguchi, Taylor L Wearda, Angela S Volk, et al.
Journal of the American Academy of Dermatology|May 20, 2019
Examining the prior authorization process, patient outcomes, and the impact of a pharmacy intervention: A single-center reviewSabrina Popatia, Kelsey S Flood, Nicole M Golbari, et al.
JAMA Dermatology|December 15, 2021
Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis: 1-Year Results From the RELIEVE-AD StudyBruce Strober, Usha G Mallya, Min Yang, et al.
Journal of the American Academy of Dermatology|January 17, 2012
Risks of developing psychiatric disorders in pediatric patients with psoriasisAlexa B Kimball, Eric Q Wu, Annie Guérin, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|January 26, 2017
The Impact of Administrative Burden on Academic Physicians: Results of a Hospital-Wide Physician SurveySandhya K Rao, Alexa B Kimball, Sara R Lehrhoff, et al.
International Journal of Women'S Dermatology|May 27, 2022
Treatment of hidradenitis suppurativa resolves associated hematologic abnormalitiesPeyton C Morss-Walton, Charlotte Greif, Zachary E Holcomb, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trialAndrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Journal of Drugs in Dermatology : JDD|August 21, 2018
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two YearsChristopher E M Griffiths, Kim A Papp, Alexa B Kimball, et al.
Pageof 23